Fig. 1From: Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact?Modification of eGFR during the 3-year follow-up period in Metformin Group (black dots) and Control Group (grey dots). For Group details, see textBack to article page